Free Trial
→ Banks aren’t ready for this altcoin—are you? (From Crypto 101 Media) (Ad)
NASDAQ:NCRA

Nocera 5/15/2025 Earnings Report

Nocera logo
$1.05 +0.04 (+3.96%)
As of 07/18/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
ProfileEarnings History

Nocera EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nocera Revenue Results

Actual Revenue
$4.53 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nocera Announcement Details

Quarter
Date
5/15/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nocera's next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Nocera Earnings Headlines

Nocera regains compliance with Nasdaq minimum bid price deficiency
July 16 at 8:09 PM  |  msn.comhttps://www.msn.com/en-us/money/companies/nocera-regains-compliance-with-nasdaq-minimum-bid-price-deficiency/ar-AA1IIzLW
Nocera Regains Nasdaq Compliance with Bid Price Rule
July 16 at 2:58 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/nocera-regains-nasdaq-compliance-with-bid-price-rule?utm_source=marketbeat.com&utm_medium=referral
Banks aren’t ready for this altcoin—are you?
The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change.
July 19 at 2:00 AM  |  Crypto 101 Media (Ad)
Nocera, Inc. Makes Strategic Investment in Tachyonext Inc. to Enter U.S. E-Commerce Market and Expand Consumer Tech Portfolio - FinanzNachrichten.de
June 26, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-06/65750617-nocera-inc-makes-strategic-investment-in-tachyonext-inc-to-enter-u-s-e-commerce-market-and-expand-consumer-tech-portfolio-200.htm
Nocera, Inc. Makes Strategic Investment in Tachyonext Inc. to Enter U.S. E-Commerce Market and Expand Consumer Tech Portfolio - Morningstar
June 26, 2025  |  morningstar.comM
Nocera faces Nasdaq compliance issue over late annual report
April 29, 2025  |  investing.comhttps://www.investing.com/news/company-news/nocera-faces-nasdaq-compliance-issue-over-late-annual-report-93CH-4007883
See More Nocera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nocera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nocera and other key companies, straight to your email.

About Nocera

Nocera (NASDAQ:NCRA) (NASDAQ: NCRA) is a clinical-stage biotechnology company focused on the development of novel RNA-based therapeutics for the treatment of rare and debilitating neurological disorders. Leveraging proprietary messenger RNA (mRNA) platforms and lipid nanoparticle delivery systems, Nocera is pioneering targeted therapeutic approaches aimed at addressing diseases with high unmet medical need. The company’s research and development pipeline encompasses several preclinical and early-stage clinical programs, including treatments for inherited neurodegenerative conditions and central nervous system injuries.

Founded in 2016 as a spin-out from a leading academic research institution, Nocera has grown its capabilities through strategic partnerships with major academic medical centers and contract research organizations. Headquartered in Boston, Massachusetts, the company maintains additional research facilities in Germany and Singapore to support global clinical trial operations and regulatory activities. Nocera’s cross-functional team includes experts in molecular biology, pharmacology, translational medicine and regulatory affairs, all working collaboratively to advance its therapeutic candidates toward proof-of-concept and registration stages.

Under the leadership of Chief Executive Officer Dr. Sarah Kim, who brings more than two decades of experience in pharmaceutical development and biotechnology, Nocera has solidified its commitment to scientific innovation and patient-centric drug development. Dr. Kim is supported by Chief Scientific Officer Dr. Mark Rodriguez, a recognized authority in RNA therapeutics, and a management team with deep expertise in manufacturing scale-up, clinical development and commercialization strategies. Together, they are guiding Nocera’s vision of transforming promising laboratory discoveries into safe and effective treatments for patients worldwide.

View Nocera Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles